Core Viewpoint - FitLife Brands, Inc. is set to participate in the 37th Annual Roth Conference on March 17-18, 2025, and will provide an updated investor presentation prior to the event [1][2]. Financial Performance Update - The company plans to report its financial performance for Q4 and the full year of 2024 on March 27, 2025, and has provided preliminary financial and operational updates [3]. - Anticipated net revenue for the full year 2024 is projected to be between $64-65 million, reflecting a 21-23% increase compared to 2023 [7]. - Adjusted EBITDA for the full year 2024 is expected to be between $14.0-14.2 million, indicating a 38-40% increase compared to 2023 [7]. - Projected net income for the full year 2024 is estimated to be between $8.9-9.1 million, representing a 68-72% increase compared to 2023 [7]. - As of December 31, 2024, the company had $13.1 million outstanding on its term loan and no balance on its revolver, with $4.5 million in cash [7]. - The number of shares outstanding as of March 12, 2025, was 9,218,528 [7]. Company Overview - FitLife Brands is a developer and marketer of innovative nutritional supplements and wellness products, offering over 250 products primarily online and through various retail locations, including GNC® franchises [3].

Core Viewpoint - FitLife Brands, Inc. is set to report its financial performance for Q4 and the full year of fiscal 2024 on March 27, 2025 [1]. Company Overview - FitLife Brands is a developer and marketer of innovative and proprietary nutritional supplements and wellness products aimed at health-conscious consumers [3]. - The company offers over 250 different products, primarily marketed online, but also available through domestic and international GNC® franchise locations and various retail outlets [3]. - FitLife Brands is headquartered in Omaha, Nebraska [3].

Core Insights - The investment philosophy emphasizes avoiding errors of commission in favor of errors of omission, as the latter are less costly [1] - The focus is on identifying clear and obvious investment opportunities that warrant significant portfolio allocation, typically 5-10% or more [1] - The approach suggests that smaller investments may not justify the effort, advocating for index fund investments instead [1] Investment Strategy - The strategy involves a concentrated investment approach, seeking opportunities that are strikingly apparent and compelling [1] - The intention is to issue fewer buy recommendations, making those that are suggested more significant [1] - The investment process includes a continuous learning aspect from the investment community, indicating a collaborative approach to investment decisions [1]

Core Viewpoint - FitLife Brands, Inc. announced a 2-for-1 forward stock split to enhance trading volumes and make the stock more accessible to a broader range of investors, reflecting confidence in the company's future [1][3]. Group 1: Stock Split Details - The forward stock split will take effect on February 7, 2025, changing the CUSIP number to 33817P405 [1]. - Prior to the split, there were 4,605,108 shares outstanding, which will increase to 9,210,216 shares post-split [2]. - The stock split does not affect stockholders' percentage ownership or voting power [2]. Group 2: Company Overview - FitLife Brands is a developer and marketer of nutritional supplements and wellness products, offering over 250 products primarily online and through GNC® franchise locations [3]. - The company is headquartered in Omaha, Nebraska, and targets health-conscious consumers [3].

Financial Performance - Total revenue for Q3 2024 was $16.0 million, a 15% increase compared to $13.9 million in Q3 2023[1][4]. - Online sales reached $10.8 million, accounting for 68% of total revenue, and increased by 14% year-over-year[2][4]. - Gross margin improved to 43.8% from 41.0% in Q3 2023[2][26]. - Net income for Q3 2024 was $2.1 million, up from $1.7 million in the same quarter last year[2][6]. - Adjusted EBITDA was $3.6 million, representing a 41% increase compared to Q3 2023[3][7]. - Wholesale revenue for Q3 2024 was $5.2 million, a 16% increase year-over-year, with acquisitions contributing $1.3 million[5][26]. - Revenue for the three months ended September 30, 2024, was $15.977 million, a 15% increase from $13.902 million in the same period of 2023[37]. - Gross profit for the nine months ended September 30, 2024, was $21.868 million, up 36% from $16.069 million in the same period of 2023[37]. - Operating income for the three months ended September 30, 2024, was $3.182 million, compared to $2.470 million in the same period of 2023, reflecting a 29% increase[37]. - Net income for the nine months ended September 30, 2024, was $6.914 million, a 81% increase from $3.816 million in the same period of 2023[37]. - Adjusted EBITDA for the nine months ended September 30, 2024, was $11,068,000, compared to $7,840,000 for the same period in 2023, reflecting a growth of 41%[42]. Cash Flow and Assets - Net cash provided by operating activities for the nine months ended September 30, 2024, was $8,653,000, up from $2,772,000 in 2023, indicating a significant improvement[38]. - Cash paid for income taxes increased to $1,105,000 for the nine months ended September 30, 2024, from $593,000 in 2023[38]. - The company reported a net cash used in investing activities of $(10,000) for the nine months ended September 30, 2024, compared to $(18,984,000) in 2023, showing a reduction in cash outflow[38]. - Cash and restricted cash at the end of the period was $4,720,000, down from $8,312,000 at the end of September 30, 2023[38]. - The foreign currency impact on cash was $54,000 for the nine months ended September 30, 2024, compared to a loss of $(3,000) in 2023[38]. - The company reported a decrease in inventories, with a change of $(1,223,000) for the nine months ended September 30, 2024, compared to an increase of $2,534,000 in 2023[38]. Debt and Liabilities - The company's net debt is approximately 0.7x adjusted LTM EBITDA, with $22.5 million borrowed for MRC and MusclePharm asset purchases, and $9.5 million remaining outstanding[31]. - Total current assets increased to $18.099 million as of September 30, 2024, from $14.693 million at the end of 2023[36]. - Total liabilities decreased to $24.429 million as of September 30, 2024, from $28.310 million at the end of 2023[36]. - The company had borrowings on term loans of $12,500,000 in the previous year, with payments on term loans amounting to $(5,875,000) in 2024[38]. Business Developments - The Company is launching the new MusclePharm Pro Series in early 2025, initially in select Vitamin Shoppe stores[23][24]. - MusclePharm Combat Sport bars and the new MusclePharm Pro Series have shown recent wins, indicating brand growth[30]. - The company continues to evaluate potential M&A opportunities, focusing on accretive, non-dilutive transactions[31]. - The MRC brands' contribution over the last twelve months was approximately $9.4 million, favorably comparing to the $17.1 million acquisition price[27]. Upcoming Events - The company will hold an investor conference call on November 14, 2024, to discuss financial results and future outlook[32]. Compensation and Expenses - The company incurred stock-based compensation of $344,000 for the nine months ended September 30, 2024, compared to $94,000 in 2023, indicating increased compensation expenses[38].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from N/A to N/A Commission File No. 000-52369 | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------------ ...

Core Viewpoint - FitLife Brands, Inc. is set to report its financial performance for Q3 of fiscal 2024 on November 14, 2024, indicating a focus on transparency and communication with investors [1]. Group 1: Financial Reporting - The company will announce its financial results for the third quarter of fiscal 2024 on November 14, 2024 [1]. - An investor conference call is scheduled for the same day at 4:30 pm ET, allowing investors to engage directly with the company's financial updates [2]. Group 2: Company Overview - FitLife Brands is a developer and marketer of innovative nutritional supplements and wellness products, catering to health-conscious consumers [3]. - The company offers over 250 different products, primarily marketed online and through GNC® franchise locations, as well as various retail outlets [3]. - FitLife Brands is headquartered in Omaha, Nebraska, emphasizing its operational base in the U.S. [3].

Company Overview - FitLife Brands Inc. (FTLF) shares increased by 5.7% to close at $32.25, following a notable trading volume, contrasting with an 8.9% loss over the past four weeks [1] - The company has achieved a year-to-date return of 65.5%, indicating strong market sentiment and consistent profitability and revenue growth in 2024 [1] Financial Performance - FitLife is expected to report quarterly earnings of $0.50 per share, reflecting a year-over-year increase of 42.9% [1] - Revenue projections for the upcoming report stand at $16.95 million, which is a 21.9% increase compared to the same quarter last year [1] Market Sentiment and Stock Trends - The consensus EPS estimate for FitLife has remained unchanged over the last 30 days, suggesting that stock price movements may stabilize without revisions in earnings estimates [2] - The stock currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [2] Industry Comparison - FitLife Brands is part of the Zacks Medical - Products industry, where BioRad Laboratories (BIO) experienced a 1% decline to $339.84, with a 5.1% return over the past month [2] - BioRad's consensus EPS estimate has decreased by 0.4% to $1.28, representing a significant year-over-year decline of 45.1%, and it currently holds a Zacks Rank of 4 (Sell) [3]

Core Insights - FitLife Brands (NASDAQ: FTLF) has been undergoing a turnaround since the appointment of CEO Dayton Judd, who has implemented successful cost-saving strategies [1] Company Overview - The company is managed by a hedge fund with a value philosophy, indicating a focus on long-term fundamentals and cost efficiency [1] Investment Philosophy - The investment approach emphasizes quality-growth companies that can provide approximately a 15% return over the next five years, with a focus on sustained top-line growth, profitability, a healthy balance sheet, free cash flow generation, high return on capital employed (ROCE), and attractive market potential [1]

Zacks recently upgraded 2 small caps from Neutral to Outperform based on recent strategy execution by these companies which appears sustainable. Fitlife Brands, Inc. (FTLF) is a provider of nutritional supplements serving the wellness and fitness markets. With a market cap of $153 m, Fitlife Brands, Inc. has $59 m of TTM sales. In Q2 Fitlife Brands (FTLF) grew revenue 14.7% YOY while adj. EBITDA grew 29%. Gross Margin increased 480 bps YOY to 44.8% as higher margin online sales now comprise nearly two-third ...